A particularly noteworthy achievement emerged this quarter: Eli Lilly's tirzepatide franchise overtook Merck's cancer immunotherapy Keytruda to become the world's highest-grossing medication. This ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

IndustryWeek champions the people and companies that make the U.S. manufacturing sector a global leader. We provide essential ...

Eli Lilly's $1.2 billion investment in Puerto Rico aims to enhance manufacturing capabilities and integrate advanced technologies for oral solid medicines. The investment is part of Lilly's broader ...

Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...

Eli Lilly will invest more than $1.2bn into its manufacturing site in Puerto Rico, as the drugmaker looks to assemble a ...

Eli Lilly’s Q3 2025 revenue jumped 54% to $17.6 billion with adjusted EPS of $7.02, prompting the company to lift its ...